{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T09:22:04Z","timestamp":1777195324380,"version":"3.51.4"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,5,15]]},"DOI":"10.2169\/internalmedicine.9466-17","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T17:16:35Z","timestamp":1515604595000},"page":"1455-1458","source":"Crossref","is-referenced-by-count":5,"title":["Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy"],"prefix":"10.2169","volume":"57","author":[{"given":"Kentaro","family":"Deguchi","sequence":"first","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Matsuzono","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syoichiro","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Hishikawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoe","family":"Ohta","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital Organization Utano National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Motomura","sequence":"additional","affiliation":[{"name":"Department of Neurology and Strokology, Nagasaki University Hospital, Japan"},{"name":"Medical Engineering Course, Department of Engineering, Faculty of Engineering, Nagasaki Institute of Applied Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2: 99-106, 2003.","DOI":"10.1016\/S1474-4422(03)00306-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368, 2001.","DOI":"10.1038\/85520"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55: 580-584, 2004.","DOI":"10.1002\/ana.20061"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135 (Pt 4): 1081-1101, 2012.","DOI":"10.1093\/brain\/aws025"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shibata-Hamaguchi A, Samuraki M, Furui E, et al. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis. Acta Neurol Scand 116: 406-408, 2007.","DOI":"10.1111\/j.1600-0404.2007.00877.x"},{"key":"6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J Diaz-Manera","year":"2012","unstructured":"6. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78: 189-193, 2012.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 14: 1029-1034, 2007.","DOI":"10.1111\/j.1468-1331.2007.01870.x"},{"key":"8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"8. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978-1980, 2003.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (Pt 10): 2304-2311, 2003.","DOI":"10.1093\/brain\/awg223"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30: 55-60, 2004.","DOI":"10.1002\/mus.20069"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakata R, Motomura M, Masuda T, et al. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. Eur J Neurol 20: 1272-1276, 2013.","DOI":"10.1111\/ene.12169"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57: 289-293, 2005.","DOI":"10.1002\/ana.20341"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 41: 370-374, 2010.","DOI":"10.1002\/mus.21533"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 1132: 76-83, 2008.","DOI":"10.1196\/annals.1405.012"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 681: 539-551, 1993.","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 82: 970-977, 2011.","DOI":"10.1136\/jnnp-2011-300148"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68: 609-611, 2007.","DOI":"10.1212\/01.wnl.0000254620.45529.97"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kornfeld P, Ambinder EP, Mittag T, et al. Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 38: 478-481, 1981.","DOI":"10.1001\/archneur.1981.00510080040003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Triantafyllou NI, Grapsa EI, Kararizou E, Psimenou E, Lagguranis A, Dimopoulos A. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up. Ther Apher Dial 13: 174-178, 2009.","DOI":"10.1111\/j.1744-9987.2009.00684.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yeh JH, Chen WH, Chiu HC, Bai CH. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. J Neurol Sci 263: 191-193, 2007.","DOI":"10.1016\/j.jns.2007.05.033"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sueoka A. Therapeutic apheresis application using membrane plasma fractionation technology: present scope and limitations. Ther Apher 4: 211-212, 2000.","DOI":"10.1046\/j.1526-0968.2000.00218.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Malik J, Tuka V, Krupickova Z, Chytilova E, Holaj R, Slavikova M. Creation of dialysis vascular access with normal flow increases brain natriuretic peptide levels. Int Urol Nephrol 41: 997-1002, 2009.","DOI":"10.1007\/s11255-009-9544-y"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/10\/57_9466-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T23:58:02Z","timestamp":1526687882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/10\/57_9466-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9466-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]}}}